Drug Profile


Alternative Names: AMD 3100; JM 3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Genzyme Corporation; Memorial Sloan-Kettering Cancer Center; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase I/II Acute myeloid leukaemia
  • Phase I Chronic lymphocytic leukaemia; Glioma; Sickle cell anaemia
  • No development reported Myocardial infarction
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 01 Sep 2016 Sanofi and Genzyme completes a phase II trial for Stem cell mobilisation in patients with multiple myeloma (Late-stage disease, Combination therapy) in Belgium, Estonia, Lithuania and Sweden (NCT01753453)
  • 25 Jul 2016 Biomarkers information updated
  • 23 Mar 2016 The University of Texas M.D. Anderson Cancer Center and Genzyme terminate a phase I/II trial in Acute myeloid leukaemia (First-line therapy, Combination therapy, in the Elderly) in USA (NCT01160354)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top